Users Stopping Anti-Obesity Jabs Gain Back Pounds Far More Rapidly Compared to People Using Diet and Exercise

Fresh analysis reveals that people who discontinue popular weight-loss injections like semaglutide or tirzepatide may regain lost weight far faster than those who stop traditional diet and exercise plans.

Published data in a major health publication demonstrates that while obese people often shed a large proportion of their body weight while using the jabs, the mass comes back at an estimated rate of nearly a kilo each month upon discontinuation.

"Users using such treatments should be aware of the danger of rapid rebound weight gain when the therapy is stopped," cautioned researcher Dr. Susan Jebb.

This pace of regain suggests a reversion to starting mass within about a year and a half.

Weighing Treatments

The research, which reviewed dozens of studies involving over 9,000 of participants, contrasted the effects of GLP-1 agonists with other pills.

Researchers emphasize that people who shed pounds through lifestyle changes alone generally experience a less rapid creep back—perhaps 0.1 kg a month—after stopping.

Explaining the Rapid Rebound

Experts propose the mechanism of the injections explains the amplified weight return.

These medications imitate a natural hormone called glucagon-like peptide-1, which moderates appetite.

"Sustained high doses of the hormone levels several times higher than the body's typical production might result in the system to generate a reduced amount of its endogenous GLP-1, and may also lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics researcher.

"Discontinuation of this medication leads to hunger is uncontrolled, making overeating far more likely."

A Chronic Disease?

Medical guidelines advise the jabs for individuals with obesity-related health risks, alongside prescribed lifestyle changes.

A number of clinicians contend that, due to the significant potential of relapse, the therapy is often long-term.

This opinion is supported by drug manufacturers, who state that the results "highlight the persistent character of obesity," comparing it to managing diseases like high blood pressure.

Patient Experiences

People who have come off the jabs report a intense resurgence of cravings.

"It was like a trigger activating and you become extremely hungry," recalled a patient.

This difficulty is worsened if users have not developed lasting lifestyle or habit changes during therapy.

Growing Adoption

Figures indicate that a significant number of people in the UK have used these injections in the past year, with demand being substantial.

• Adoption is more common among females than men.
• The 40s and 50s demographic shows the highest usage rates.
• Many access the drugs through private healthcare rather than the NHS.

Ultimately, experts stress that while GLP-1 drugs are powerful tools for weight loss, they are not a permanent cure and long-term success hinges on integrated behavioural support.